Evaluation of whole sporozoite vaccines for malaria elimination
This program of work is led by a clinical team at the Ifakara Health Institute Clinical Trial Facility at Kingani, Bagamoyo (IHI – CTF) which is conducting a series of studies to evaluate the potential impact of whole sporozoite malaria vaccine candidates to prevent malaria infection and thereby block transmission with the goal of achieving malaria elimination in Sub-Sahara Africa. The work is conducted in two countries; Tanzania and Equatorial Guinea. Studies and major contributions of the work to date include:
BSPZC1 (NCT01540903): The first Controlled Human Malaria Infection (CHMI) study using purified fully infectious malaria sporozoites in an African country was conducted at IHI-CTF at Kingani, Bagamoyo in 2012. This trial demonstrated the safety and infectivity of the fully infectious purified sporozoites (PfSPZ Challenge) leading to the establishment of the CHMI model for testing new malaria vaccines and drugs in Africa
BSPZV1 (NCT02132299): Study conducted in IHI-CTF at Kingani, Bagamoyo between 2014-2015. This was the first PfSPZ Vaccine (radiation attenuated sporozoites) trial to be conducted in Africa. The trial established a very good safety and tolerability profile for the PfSPZ vaccine and was the basis for further studies in Mali and Equatorial Guinea.
BSPZV2 (NCT02613520): Study conducted in IHI-CTF at Kingani, Bagamoyo between 2015- 2016. Worldwide, this was the first PfSPZ Vaccine (radiation attenuated sporozoites) trial in adolescents and children. The trial established a very good safety and tolerability profile for PFSPZ vaccine in younger age groups and well as better immune responses in younger children. This work was the basis for further studies in Equatorial Guinea, Kenya and other African countries.